Precision BioSciences Inc (DTIL)

[jondoeuk]

Thanks for posting jondo, do you know if that is a new population or an update on the first set in the below?

The trial is ongoing, and as of Feb 1, thirteen patients met the eligibility criteria and had received DL3, with either standard or enhanced lymphodepletion. At the event there will be additional data, including durability. Also, the company will hold a conference call.

I find the abstract results rather impressive. Am I missing something?

Yes, it is, but the numbers are small. If more (n=30-50) who have enhanced lymphodepletion, show a similar ORR, CR rate at six months and safety profile as autologous CAR-T's, I don't see why a registration directed PhII trial couldn't happen.